Efficacy Studies against PCV-2 of a New Trivalent Vaccine including PCV-2a and PCV-2b Genotypes and Mycoplasma hyopneumoniae When Administered at 3 Weeks of Age.
Vaccines (Basel). 2022 Dec 9;10(12):2108. doi: 10.3390/vaccines10122108.
Vaccines (Basel). 2022.
PMID: 36560518
Free PMC article.